
You are here: Technologies » NanoCrystalŽ Technology » Depot Delivery
Significant work has been undertaken in applying the NanoCrystal® technology to injectable depot delivery. Janssen’s (J&J’s) one month paliperidone palmitate (Invega® Sustenna™) depot injection which was approved in July 2009 by the US FDA, uses EDT’s NanoCrystal® technology. Another depot delivery compound is undergoing Phase I studies.
In this example, a long-acting depot of an otherwise insoluble compound has been developed.
.gif)
Elan Corporation, plc. Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Registered in Ireland, Number 30356.